KRAS and lung carcinoma: To determine the frequency of co-occurring KRAS mutations in NSCLC and potential impact on the response to KRAS G12C-specific inhibitors, we assessed the KRAS mutation status in a large cohort of locally advanced or metastatic NSCLC samples (n = 2306), assayed for enrolment into the SELECT-1 phase 3 trial (NCT01933932), and examined how some of these co-occurring mutations influence response of lung cancer in vitro models to the KRAS G12C-specific inhibitor AZ’8037 (also known as “compound 25”)24.